XtalPi Announces the Closing of $46 Million Series B-1 Extension

to drive growth and accelerate platform development.

Building an AI-powered Drug R&D Engine

to empower pharmaceutical research with increased efficiency and success rate.

How Quantum Physics and AI is Disrupting Drug Discovery & Development

Case study on how XtalPi is helping Pfizer scientists predict and optimize the crystalline forms of drug candidates.

XtalPi Hosts Rational Solid Form Design Summit

bridging the gap between newly available technologies and pharmaceutical research in solid state science.

XtalPi Announces the Closing of $46 Million Series B-1 Extension

to drive growth and accelerate platform development.

Building an AI-powered Drug R&D Engine

to empower pharmaceutical research with increased efficiency and success rate.

Drug Solid-State R&D

For solid-state R&D of small molecule drugs, the XtalPi solution integrates several state-of-the-art technologies for crystal structure prediction, crystal structure determination, virtual screening of salts and cocrystals, as well as an advanced solid-state R&D experimental platform. The company is dedicated to creating the next-generation platform for solid-state R&D for small molecules by combining experimental screening and characterization with theoretical calculations and analyses, and providing novel solutions for the solid-state R&D. At XtalPi, we help our clients improve the quality and efficiency of solid-state R&D and reduce R&D risks and costs.

...
XtalPi Research on SARS-CoV-2 (Updated)

XtalPi team shares the timeline and preliminary results on their research of the new coronavirus.

...
XtalPi Announces Strategic Collaboration with Porton

Combining AI Algorithms with Targeted Experiments to Solve Bottleneck Challenges in Drug Development

...
How Quantum Physics and AI is Disrupting Drug Discovery & Development

Case study on how XtalPi is helping pfizer scientists predict and optimize the crystalline forms of drug candidates.

Our Partners